Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition (Nasdaq: ACOG) will report third-quarter 2026 financial results and provide a business update on November 11, 2026. The announcement is scheduled for 4:30 p.m. Eastern Time, after market close. Management will host a conference call following the release to review financial and operating results. Results and accompanying materials will be available in the website’s News section, with a call replay available three hours afterward in the Events section.
Alpha Cognition (ACOG) announced publication of a U.S. patent application covering its proprietary manufacturing process for benzgalantamine, the active ingredient in ZUNVEYL.
The USPTO published application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as US 2026/0297103 A1. Alpha Cognition said the technology is intended to support consistent commercial-scale production of high-purity benzgalantamine. The application describes methods for controlling product characteristics relevant to manufacturing reliability and stability.
Alpha Cognition (ACOG) will present new ZUNVEYL clinical and real-world data at the ASCP Annual Meeting and NEI Fall Congress.
ASCP takes place October 29-November 1, 2026, followed by NEI on November 5-8, 2026. The scheduled posters examine cognition, daily functioning, neuropsychiatric symptoms, sleep, gastrointestinal tolerability and medication use in residents with Alzheimer’s disease, primarily in long-term care. ASCP presentations also cover treatment transitions to benzgalantamine, ZUNVEYL’s drug name, and a subgroup previously treated with donepezil. NEI presentations focus on cognitive and functional outcomes and symptom and medication-use analyses from the BEACON Study. An ASCP literature review addresses acetylcholinesterase inhibitors, a class of Alzheimer’s treatments, and CMS psychotropic quality measures.
Alpha Cognition (ACOG) granted stock options covering 6,000 common shares to a new non-executive employee on October 1, 2026.
The Compensation Committee approved the award under the 2026 Inducement Grant Plan as an employment inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $8.70 per share, equal to the closing share price on the grant date. The options vest over three years: one-third on the first anniversary of the grant and the remaining two-thirds in equal quarterly installments over the following two years. Vesting requires the employee’s continued service through each applicable vesting date.
Alpha Cognition (ACOG) announced initial CONVERGE results comparing ZUNVEYL dosing and other medication use with generic therapies in long-term care residents.
The ongoing retrospective analysis assessed 180-day patterns. Among residents new to acetylcholinesterase inhibitors, drugs that inhibit an enzyme that breaks down acetylcholine, and starting at the initial dose, 79.1% reached therapeutic dosing with ZUNVEYL versus 37.3% with pooled generics. Across all starting doses, rates were 79.2% versus 53.7% for new users and 80.7% versus 54.0% for residents previously treated with another such drug. Other medication-class burden decreased across all eight evaluated classes with ZUNVEYL and increased with generics.
The analyses were unadjusted for potential confounders and do not establish causality. Alpha Cognition expects dataset updates in December 2026 and March 2027 to expand future analyses.
Alpha Cognition (ACOG) granted an inducement award of nonstatutory stock options to purchase 25,000 common shares to a new non-executive employee on September 8, 2026, under its 2026 Inducement Grant Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $9.52 per share, equal to the closing price of the company’s stock on the grant date. Vesting occurs over three years: one-third on the first anniversary of the grant, and the remaining two-thirds in equal quarterly installments over the following two years, subject to continued service. The options are governed by the 2026 Inducement Grant Plan and an applicable stock option agreement. Alpha Cognition is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases and markets the Alzheimer’s treatment ZUNVEYL.
Alpha Cognition (NASDAQ: ACOG) reported that its Board Compensation Committee granted an inducement award of nonstatutory stock options to purchase 20,000 common shares to a new non-executive employee under the 2026 Inducement Grant Plan. The options, granted August 31, 2026, have an exercise price of $9.27 per share, equal to the closing market price that day. Vesting will occur over three years, with one-third after the first anniversary and the remaining two-thirds in equal quarterly installments over the following two years, subject to continued service. The grant was approved as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4).
Alpha Cognition (NASDAQ: ACOG) was the subject of an updated coverage report by Stonegate Capital Partners following 2Q26 results that support the ongoing launch of ZUNVEYL. Net product revenue rose 71% quarter-over-quarter to $6.0 million, driven by a 37% increase in bottles dispensed to 8,294, with June reaching 2,997 bottles, the strongest month since launch. Stonegate notes there was no material stocking benefit and downstream PBM implementation remained at about 16%.
Prescriber and facility adoption expanded, with 1,347 quarterly prescribers, 1,024 repeat prescribers, 1,908 cumulative writers and 1,095 long-term care facilities generating prescriptions. Alpha Cognition lowered FY26 R&D and SG&A guidance to $50–$54 million while maintaining its 2027 operating profitability target. According to the company, CONVERGE data are expected in 3Q26, RESOLVE is underway and the sublingual program depends on comparative PK results, creating several upcoming milestones.
Alpha Cognition (NASDAQ: ACOG) reported Q2 2026 ZUNVEYL net product revenue of approximately $6.0 million, up about 71% quarter-over-quarter from $3.5 million. Bottles dispensed rose 37% to 8,294, quarterly prescribers increased 26% to 1,347, and repeat prescribers grew 29% to 1,024, with roughly 76% prescribing in multiple months.
Long-term care penetration reached 1,095 facilities. Gross margin was 94%, with cost of product sales of $0.35 million. R&D expenses were $2.0 million and SG&A $11.5 million, driving an operating loss of $7.8 million and net loss of $8.8 million ($0.40 per share). Cash and equivalents totaled $41.4 million, and full-year 2026 R&D and SG&A guidance was reduced to $50–$54 million. The company highlighted positive BEACON study topline results, ongoing CONVERGE and RESOLVE studies, and a sublingual formulation targeting the clinic in 2027.
Alpha Cognition (Nasdaq: ACOG) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. A press release with results and highlights will be posted in the News section of the company’s website.
According to Alpha Cognition, management will host a conference call and webcast to review financial and operating results. Investors can join via toll-free number 1-877-407-9039, international number 1-201-689-8470, Call me link, or webcast. A replay will be available about three hours after the call in the Events section of the website, with replay dial-in 1-844-512-2921 or 1-412-317-6671 using Access ID 137611178.